Printer Friendly

BRISTOL-MYERS SQUIBB ANNOUNCES TWO EXECUTIVE CHANGES

 NEW YORK, Nov. 29 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced two executive changes today.
 Michael E. Autera, Executive Vice President, will head the company's Nutritional and Health Care businesses. Mr. Autera will continue in his role as Chief Financial Officer until a successor is named.
 William F. Flatley, Senior Vice President, will assume responsibility for business strategy, the company's productivity enhancement initiatives and coordination of the restructuring effort of the Corporate Staff organization.


Mr. Flatley will retain responsibility for Corporate Hospital Accounts, which works with group purchasers of the company's various products.
 Both executives' new responsibilities become effective Jan. 1, 1994. They will report to Charles A. Heimbold, Jr., President. As announced previously, Mr. Heimbold will become Chief Executive Officer, effective Jan. 1, 1994. Richard L. Gelb will continue as Chairman of the company.
 The Nutritional and Health Care businesses are comprised of Mead Johnson (nutritionals), Convatec (ostomy and wound care products), Zimmer (orthopaedic devices and surgical instruments) and Linvatec (least invasive surgery products).
 Mr. Autera joined Bristol-Myers Squibb in 1966. He became Controller in 1973 and Chief Financial Officer in 1977. He was named Executive Vice President, Administration and Chief Financial Officer in 1989. In 1991 he was elected a Director of the company.
 Mr. Flatley joined Bristol-Myers Squibb in 1980. In 1984 he was named President of the company's Drackett division. In 1988 he was named Senior Vice President, Human Resources for Bristol-Myers Squibb. He was promoted to the position of President, Health Care Group in 1991 and later assumed the additional responsibility for Corporate Hospital Accounts.
 The company's Pharmaceutical and Consumer businesses will continue to report directly to Mr. Heimbold.
 Bristol-Myers Squibb is a diversified, research-based health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices.
 -0- 11/29/93
 /CONTACT: Jon Weisberg of Bristol-Myers Squibb, 212-546-4343/
 (BMY)


CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU: PER

SH -- NY052 -- 8299 11/29/93 12:35 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 29, 1993
Words:326
Previous Article:VF NAMES NEW PRESIDENTS OF MARITHE & FRANCOIS GIRBAUD AND HEALTHTEX DIVISIONS
Next Article:SURGICAL CARE SETS DEC. 7 DEADLINE FOR TALKS WITH MEDICAL CARE AMERICA
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters